Is Goldman Sachs Stock a Buy Sell or Hold?
When the Federal Reserve started hiking rates in 2022, banks’…
Sell
48
AKTX Quote, Financials, Valuation and Earnings
Last price:
$0.97
Seasonality move
:
-3.6%
Day range:
$0.93 - $1.05
52-week range:
$0.85 - $4.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.34x
Volume:
8.6K
Avg. volume:
29.1K
1-year change:
-48.53%
Market cap:
$26M
Revenue:
--
EPS (TTM):
-$2.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AKTX
Akari Therapeutics PLC
|
-- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics PLC
|
$4.2M | -$0.27 | -61.82% | -46.14% | $10.45 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
DBVT
DBV Technologies SA
|
$1.1M | -$0.24 | -- | -59.89% | $21.81 |
|
NCNA
NuCana PLC
|
-- | -$2.20 | -- | -98.11% | $64.50 |
|
VRNA
Verona Pharma PLC
|
$68.4M | -$0.02 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AKTX
Akari Therapeutics PLC
|
$1.05 | -- | $26M | -- | $0.00 | 0% | -- |
|
AUTL
Autolus Therapeutics PLC
|
$1.87 | $10.45 | $497.6M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.90 | $17.97 | $1.3M | -- | $0.00 | 0% | 1.71x |
|
DBVT
DBV Technologies SA
|
$4.87 | $21.81 | $99.9M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.76 | $64.50 | $3M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$61.39 | $81.00 | $5.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AKTX
Akari Therapeutics PLC
|
-- | 0.585 | -- | -- |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.987 | -- | 17.97x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 0.756 | -- | 1.20x |
|
DBVT
DBV Technologies SA
|
-- | -0.036 | -- | -- |
|
NCNA
NuCana PLC
|
-- | 0.645 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | -0.759 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AKTX
Akari Therapeutics PLC
|
-- | -$1.9M | -- | -- | -- | -$1.5M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
DBVT
DBV Technologies SA
|
-- | -$30.3M | -- | -- | -- | -$22.9M |
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
Akari Therapeutics PLC vs. Competitors
-
Which has Higher Returns AKTX or AUTL?
Autolus Therapeutics PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of -522.15%. Akari Therapeutics PLC's return on equity of -- beat Autolus Therapeutics PLC's return on equity of -80.74%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics PLC-- -$0.24 -- AUTLAutolus Therapeutics PLC-- -$0.31 $582M -
What do Analysts Say About AKTX or AUTL?
Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 7519.05%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.45 which suggests that it could grow by 468.03%. Given that Akari Therapeutics PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe Akari Therapeutics PLC is more attractive than Autolus Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics PLC0 0 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is AKTX or AUTL More Risky?
Akari Therapeutics PLC has a beta of 0.895, which suggesting that the stock is 10.528% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.067, suggesting its more volatile than the S&P 500 by 106.723%.
-
Which is a Better Dividend Stock AKTX or AUTL?
Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or AUTL?
Akari Therapeutics PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $10.1M. Akari Therapeutics PLC's net income of -$2.9M is higher than Autolus Therapeutics PLC's net income of -$82.1M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics PLC-- -- -- -$2.9M AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M
-
Which has Higher Returns AKTX or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics PLC-- -$0.24 -- BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About AKTX or BDRX?
Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 7519.05%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 852.19%. Given that Akari Therapeutics PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe Akari Therapeutics PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics PLC0 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is AKTX or BDRX More Risky?
Akari Therapeutics PLC has a beta of 0.895, which suggesting that the stock is 10.528% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.
-
Which is a Better Dividend Stock AKTX or BDRX?
Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or BDRX?
Akari Therapeutics PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Akari Therapeutics PLC's net income of -$2.9M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 1.71x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics PLC-- -- -- -$2.9M BDRXBiodexa Pharmaceuticals PLC1.71x -- -- --
-
Which has Higher Returns AKTX or DBVT?
DBV Technologies SA has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics PLC-- -$0.24 -- DBVTDBV Technologies SA-- -$1.60 -- -
What do Analysts Say About AKTX or DBVT?
Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 7519.05%. On the other hand DBV Technologies SA has an analysts' consensus of $21.81 which suggests that it could grow by 347.91%. Given that Akari Therapeutics PLC has higher upside potential than DBV Technologies SA, analysts believe Akari Therapeutics PLC is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics PLC0 0 0 DBVTDBV Technologies SA0 0 0 -
Is AKTX or DBVT More Risky?
Akari Therapeutics PLC has a beta of 0.895, which suggesting that the stock is 10.528% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.707, suggesting its less volatile than the S&P 500 by 29.271%.
-
Which is a Better Dividend Stock AKTX or DBVT?
Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or DBVT?
Akari Therapeutics PLC quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Akari Therapeutics PLC's net income of -$2.9M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics PLC-- -- -- -$2.9M DBVTDBV Technologies SA-- -- -- -$30.4M
-
Which has Higher Returns AKTX or NCNA?
NuCana PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics PLC-- -$0.24 -- NCNANuCana PLC-- -$2.28 -- -
What do Analysts Say About AKTX or NCNA?
Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 7519.05%. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 8381.26%. Given that NuCana PLC has higher upside potential than Akari Therapeutics PLC, analysts believe NuCana PLC is more attractive than Akari Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics PLC0 0 0 NCNANuCana PLC1 1 0 -
Is AKTX or NCNA More Risky?
Akari Therapeutics PLC has a beta of 0.895, which suggesting that the stock is 10.528% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.789%.
-
Which is a Better Dividend Stock AKTX or NCNA?
Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or NCNA?
Akari Therapeutics PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Akari Therapeutics PLC's net income of -$2.9M is higher than NuCana PLC's net income of -$5.9M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics PLC-- -- -- -$2.9M NCNANuCana PLC-- -- -- -$5.9M
-
Which has Higher Returns AKTX or VRNA?
Verona Pharma PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of -92.29%. Akari Therapeutics PLC's return on equity of -- beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics PLC-- -$0.24 -- VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About AKTX or VRNA?
Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 7519.05%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 31.94%. Given that Akari Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Akari Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics PLC0 0 0 VRNAVerona Pharma PLC5 0 0 -
Is AKTX or VRNA More Risky?
Akari Therapeutics PLC has a beta of 0.895, which suggesting that the stock is 10.528% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.803%.
-
Which is a Better Dividend Stock AKTX or VRNA?
Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or VRNA?
Akari Therapeutics PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. Akari Therapeutics PLC's net income of -$2.9M is higher than Verona Pharma PLC's net income of -$33.8M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics PLC-- -- -- -$2.9M VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Reddit a Buy on the Dip?
Reddit (NYSE:RDDT) share price has been on the proverbial ropes…
Qualcomm Stock: 5G Leader at a Bargain Price?
Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
59
GRRR alert for Mar 15
Gorilla Technology Group [GRRR] is up 29.72% over the past day.
Sell
49
SMTC alert for Mar 15
Semtech [SMTC] is up 21.28% over the past day.
Buy
62
PLPC alert for Mar 15
Preformed Line Products [PLPC] is up 17.38% over the past day.
